Showing 941 - 950 of 1,415
A systematic review of the literature was conducted to give an overview of economic evaluations of preventive interventions in type 2 diabetes mellitus. The interventions were sorted by type of preventive intervention (primary, secondary or tertiary) and by category (e.g. education, medication...
Persistent link: https://www.econbiz.de/10005243149
Background: Discontinuation of benzodiazepine usage has never been evaluated in economic terms. This study aimed to compare the relative costs and outcomes of tapering off long-term benzodiazepine use combined with group cognitive behavioural therapy (TO+CBT), tapering off alone (TOA) and usual...
Persistent link: https://www.econbiz.de/10005243152
Cost-effectiveness acceptability curves (CEACs) are a method used to present uncertainty surrounding incremental cost-effectiveness ratios (ICERs). Construction of the curves relies on the assumption that the willingness to pay (WTP) for health gain is identical to the willingness to accept...
Persistent link: https://www.econbiz.de/10005243158
Persistent link: https://www.econbiz.de/10005243159
Persistent link: https://www.econbiz.de/10005243160
We reviewed the literature on the efficacy and effectiveness of beta-blocker therapy and examined the economic consequences of under-utilisation. Despite the literature documenting the value of beta-blockers, the therapy is not prescribed at the appropriate rates. Approximately half of acute...
Persistent link: https://www.econbiz.de/10005243162
Persistent link: https://www.econbiz.de/10005243170
Interest in the use of economic evaluations in Korea as an aid for healthcare decision makers has been growing rapidly since the financial crisis of the Korean National Health Insurance fund and the separation in 2000 of the roles of prescribing and dispensing drugs. The Korean Health Insurance...
Persistent link: https://www.econbiz.de/10005243174
Objective: To compare the cost effectiveness of sequential intravenous (IV) to oral ciprofloxacin plus metronidazole (CIP/MTZ IV/PO) with that of IV ciprofloxacin plus IV metronidazole (CIP/MTZ IV) and IV imipenem-cilastatin (IMI IV) in patients with intra-abdominal infections. Design and...
Persistent link: https://www.econbiz.de/10005243176
High-intermediate grade non-Hodgkin Despite a significant rise in the incidence of NHL over recent years, there remains only limited published economic study concerning the overall lifetime cost of treatment, the cost effectiveness of specific treatments or the overall societal cost burden of...
Persistent link: https://www.econbiz.de/10005243182